Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

SunTrust (STI) Rewards Shareholders With 12% Dividend Hike

Published 08/14/2019, 09:18 PM
Updated 07/09/2023, 06:31 AM

SunTrust Banks, Inc.’s (NYSE:STI) board of directors approved a 12% hike in the quarterly common stock dividend. The revised quarterly dividend is now 56 cents per share, up from the prior payout of 50 cents. This dividend is payable on Sep 16 to shareholders of record as of Aug 30.

Since 2013, SunTrust has been raising its dividend annually. Prior to this hike, the company hiked its dividend by 25% (from 40 cents to 50 cents per share) in August 2018.

We remain optimistic about SunTrust’s potential to continue enhancing shareholder value, driven by its strong cash generation capabilities.

In the biggest bank deal since the 2007-2009 financial crisis, the company will be acquired by BB&T Corp (NYSE:BBT) for $66 billion in an all-stock merger.

Per the terms of the deal, BB&T shareholders will own roughly 57% and SunTrust shareholders will own around 43% of the combined entity. Moreover, SunTrust shareholders will receive a 5% increase in their dividend upon the completion of the deal.

Notably, given SunTrust’s exemption from the Federal Reserve's annual stress tests in accordance with the Economic Growth, Regulatory Relief and Consumer Protection Act of 2018, the company has flexibility in announcing capital plans.

Some other finance companies like KeyCorp (NYSE:KEY) and Zions Bancorporation (NASDAQ:ZION) have also been exempted from the Federal Reserve's annual stress tests.

Given SunTrust’s solid liquidity position, earnings strength and lower debt level, it will likely retain its improved capital deployments and continue enhancing shareholder value moving ahead.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

BB&T Corporation (BBT): Free Stock Analysis Report

KeyCorp (KEY): Free Stock Analysis Report

SunTrust Banks, Inc. (STI): Free Stock Analysis Report

Zions Bancorporation (ZION): Free Stock Analysis Report

Original post

Zacks Investment Research

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.